此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Belzutifan (MK-6482) 和 Zanzalintinib 在肾细胞癌 (RCC) 患者中的临床研究 (LITESPARK-034/LS-034/MK-6482-034)

2026年11月12日 更新者:Merck Sharp & Dohme LLC

一项关于Belzutifan + Zanzalintinib对比Belzutifan + 安慰剂在序贯或联合接受PD-1/L1和VEGF-TKI治疗后进展的晚期RCC患者中的3期随机双盲研究(LITESPARK-034)

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).

A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.

The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.

研究概览

研究类型

介入性

注册 (估计的)

758

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Capital Region
      • Herlev、Capital Region、丹麦、2730
        • 招聘中
        • Herlev Hospital ( Site 1002)
        • 接触:
          • Study Coordinator
          • 电话号码:00 45 38689191
    • Central Jutland
      • Aarhus、Central Jutland、丹麦、8200
        • 招聘中
        • Aarhus Universitetshospital, Skejby ( Site 1001)
        • 接触:
          • Study Coordinator
          • 电话号码:+4591167472
    • Region Syddanmark
      • Odense、Region Syddanmark、丹麦、5000
        • 招聘中
        • Odense Universitets Hospital ( Site 1000)
        • 接触:
          • Study Coordinator
          • 电话号码:+4566113333
      • Haifa、以色列、3109601
        • 招聘中
        • Rambam Health Care Campus ( Site 1600)
        • 接触:
          • Study Coordinator
          • 电话号码:+97247772688
      • Kfar Saba、以色列、4428164
        • 招聘中
        • Meir Medical Center. ( Site 1603)
        • 接触:
          • Study Coordinator
          • 电话号码:+97297472555
      • Petah Tikva、以色列、4941492
        • 招聘中
        • Rabin Medical Center ( Site 1602)
        • 接触:
          • Study Coordinator
          • 电话号码:97239378074
      • Ramat Gan、以色列、5265601
        • 招聘中
        • Sheba Medical Center ( Site 1601)
        • 接触:
          • Study Coordinator
          • 电话号码:97235303030
    • Ontario
      • Ottawa、Ontario、加拿大、K1H 8L6
        • 招聘中
        • The Ottawa Hospital Cancer Centre ( Site 0003)
        • 接触:
          • Study Coordinator
          • 电话号码:613-737-7700
    • Quebec
      • Québec、Quebec、加拿大、G1J 1Z4
        • 招聘中
        • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
        • 接触:
          • Study Coordinator
          • 电话号码:418-525-4444
      • Adana、土耳其(türkiye)、01140
        • 招聘中
        • Adana Medical Park Seyhan Hastanesi ( Site 2505)
        • 接触:
          • Study Coordinator
          • 电话号码:+905372688986
      • Ankara、土耳其(türkiye)、06620
        • 招聘中
        • Ankara University Health Practice and Research Hospitals ( Site 2506)
        • 接触:
          • Study Coordinator
          • 电话号码:+90 312 595 71 12
      • Edirne、土耳其(türkiye)、22030
        • 招聘中
        • Trakya University Medical Faculty Hospital ( Site 2502)
        • 接触:
          • Study Coordinator
          • 电话号码:+9005378528123
      • Istanbul、土耳其(türkiye)、34010
        • 招聘中
        • Koc Universitesi Hastanesi ( Site 2501)
        • 接触:
          • Study Coordinator
          • 电话号码:0090 850 250 8 250
      • Izmir、土耳其(türkiye)、35080
        • 招聘中
        • Ege Universitesi Hastanesi ( Site 2503)
        • 接触:
          • Study Coordinator
          • 电话号码:0 232 343 43 43
    • Ankara
      • Sıhhiye、Ankara、土耳其(türkiye)、06230
        • 招聘中
        • Hacettepe Universite Hastaneleri ( Site 2500)
        • 接触:
          • Study Coordinator
          • 电话号码:+905439340493
    • Espírito Santo
      • Vitória、Espírito Santo、巴西、29055-450
        • 招聘中
        • CEDOES ( Site 0303)
        • 接触:
          • Study Coordinator
          • 电话号码:+552721250202
    • Paraná
      • Curitiba、Paraná、巴西、80510-130
        • 招聘中
        • Instituto do Câncer e Transplante de Curitiba ( Site 0300)
        • 接触:
          • Study Coordinator
          • 电话号码:+55 41 99205-7755
    • Rio Grande do Norte
      • Natal、Rio Grande do Norte、巴西、59062-000
        • 招聘中
        • Liga Norte Riograndense Contra o Câncer ( Site 0307)
        • 接触:
          • Study Coordinator
          • 电话号码:+55 84 4009-5595
    • São Paulo
      • Ribeirão Preto、São Paulo、巴西、14026-610
        • 招聘中
        • Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
        • 接触:
          • Study Coordinator
          • 电话号码:+55 16 3913-8181
      • São José do Rio Preto、São Paulo、巴西、15090-000
        • 招聘中
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
        • 接触:
          • Study Coordinator
          • 电话号码:+55 17 3201-5054
    • Attica
      • Athens、Attica、希腊、185 47
        • 招聘中
        • Metropolitan Hospital ( Site 1402)
        • 接触:
          • Study Coordinator
          • 电话号码:+302104809667
      • Athens、Attica、希腊、124 62
        • 招聘中
        • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
        • 接触:
          • Study Coordinator
          • 电话号码:+302105832549
      • Athens、Attica、希腊、115 28
        • 招聘中
        • Alexandra General Hospital of Athens ( Site 1400)
        • 接触:
          • Study Coordinator
          • 电话号码:+302132162543
      • Berlin、德国、10117
        • 招聘中
        • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
        • 接触:
          • Study Coordinator
          • 电话号码:+4930450515288
    • Bavaria
      • Augsburg、Bavaria、德国、86156
        • 招聘中
        • Universitaetsklinikum Augsburg ( Site 1316)
        • 接触:
          • Study Coordinator
          • 电话号码:+498214002348
      • Munich、Bavaria、德国、81675
        • 招聘中
        • klinikum rechts der isar der technischen universität münchen ( Site 1315)
        • 接触:
          • Study Coordinator
          • 电话号码:00498941402522
    • Thuringia
      • Jena、Thuringia、德国、07747
        • 招聘中
        • Universitätsklinikum Jena ( Site 1313)
        • 接触:
          • Study Coordinator
          • 电话号码:+4936419329970
      • Bari、意大利、70124
        • 招聘中
        • Azienda Ospedaliera Policlinico di Bari ( Site 1802)
        • 接触:
          • Study Coordinator
          • 电话号码:00390805593767
      • Bologna、意大利、40138
        • 招聘中
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
        • 接触:
          • Study Coordinator
          • 电话号码:+390512142204
      • Milan、意大利、20133
        • 招聘中
        • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
        • 接触:
          • Study Coordinator
          • 电话号码:02 2390 3028
      • Perugia、意大利、06132
        • 招聘中
        • AO Santa Maria della Misericordia ( Site 1805)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0755784188
      • Roma、意大利、00168
        • 招聘中
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
        • 接触:
          • Study Coordinator
          • 电话号码:00390630155202
      • Roma、意大利、00144
        • 招聘中
        • Istituto Nazionale Tumori Regina Elena ( Site 1804)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0652666919
    • Emilia-Romagna
      • Meldola、Emilia-Romagna、意大利、47014
        • 招聘中
        • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
        • 接触:
          • Study Coordinator
          • 电话号码:+390543739100
    • Milano
      • Rozzano、Milano、意大利、20089
        • 招聘中
        • Istituto Clinico Humanitas ( Site 1808)
        • 接触:
          • Study Coordinator
          • 电话号码:0282244061
    • Treviso
      • Castelfranco Veneto、Treviso、意大利、31033
        • 招聘中
        • Istituto Oncologico Veneto IRCCS ( Site 1806)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0423732336
    • Tuscany
      • Florence、Tuscany、意大利、50134
        • 招聘中
        • Azienda Ospedaliera Universitaria Careggi ( Site 1807)
        • 接触:
          • Study Coordinator
          • 电话号码:+390557949648
      • Hradec Králové、捷克语、500 05
        • 招聘中
        • Fakultni nemocnice Hradec Kralove ( Site 0902)
        • 接触:
          • Study Coordinator
          • 电话号码:+420727854666
      • Olomouc、捷克语、779 00
        • 招聘中
        • Fakultni nemocnice Olomouc ( Site 0901)
        • 接触:
          • Study Coordinator
          • 电话号码:+420588445923
      • Prague、捷克语、150 06
        • 招聘中
        • Fakultni nemocnice v Motole ( Site 0900)
        • 接触:
          • Study Coordinator
          • 电话号码:+420734236410
      • Prague、捷克语、128 08
        • 招聘中
        • Fakulti poliklinika ( Site 0906)
        • 接触:
          • Study Coordinator
          • 电话号码:+420224966405
    • Brno-mesto
      • Brno、Brno-mesto、捷克语、656 53
        • 招聘中
        • Masarykuv onkologicky ustav ( Site 0903)
        • 接触:
          • Study Coordinator
          • 电话号码:+420543132216
    • Ostrava Mesto
      • Ostrava、Ostrava Mesto、捷克语、708 52
        • 招聘中
        • Fakultni nemocnice Ostrava ( Site 0904)
        • 接触:
          • Study Coordinator
          • 电话号码:+420597374322
    • Coquimbo Region
      • La Serena、Coquimbo Region、智利、1720430
        • 招聘中
        • IC La Serena Research ( Site 0405)
        • 接触:
          • Study Coordinator
          • 电话号码:56958646664
    • Los Lagos Region
      • Port Montt、Los Lagos Region、智利、5500243
        • 招聘中
        • Clínica Puerto Montt ( Site 0404)
        • 接触:
          • Study Coordinator
          • 电话号码:+56985383586
    • Region M. de Santiago
      • Santiago、Region M. de Santiago、智利、7500921
        • 招聘中
        • Fundacion Arturo Lopez Perez ( Site 0401)
        • 接触:
          • Study Coordinator
          • 电话号码:56224205098
      • Santiago、Region M. de Santiago、智利、8420383
        • 招聘中
        • Bradfordhill ( Site 0400)
        • 接触:
          • Study Coordinator
          • 电话号码:56229490970
    • Valparaiso
      • Viña del Mar、Valparaiso、智利、2520598
        • 招聘中
        • ONCOCENTRO APYS ( Site 0403)
        • 接触:
          • Study Coordinator
          • 电话号码:56323320850
    • Alpes-Maritimes
      • Nice、Alpes-Maritimes、法国、06189
        • 招聘中
        • Centre Antoine Lacassagne ( Site 1209)
        • 接触:
          • Study Coordinator
          • 电话号码:+33492031538
    • Bouches-du-Rhone
      • Marseille、Bouches-du-Rhone、法国、13003
        • 招聘中
        • Hopital Europeen Marseille ( Site 1216)
        • 接触:
          • Study Coordinator
          • 电话号码:+33413427427
    • Haute-Garonne
      • Toulouse、Haute-Garonne、法国、31059
        • 招聘中
        • LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
        • 接触:
          • Study Coordinator
          • 电话号码:+33531155050
    • Maine-et-Loire
      • Angers、Maine-et-Loire、法国、49933
        • 招聘中
        • CHU Angers ( Site 1204)
        • 接触:
          • Study Coordinator
          • 电话号码:+33241354694
    • Pays de la Loire Region
      • Le Mans、Pays de la Loire Region、法国、72000
        • 招聘中
        • Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
        • 接触:
          • Study Coordinator
          • 电话号码:+33 243297908
      • Saint Priest En Jarez、Pays de la Loire Region、法国、42271
        • 招聘中
        • CHU de Saint-Etienne ( Site 1202)
        • 接触:
          • Study Coordinator
          • 电话号码:+33477917082
    • Val-de-Marne
      • Villejuif、Val-de-Marne、法国、94800
        • 招聘中
        • Gustave Roussy ( Site 1214)
        • 接触:
          • Study Coordinator
          • 电话号码:+33142114211
    • Greater Poland Voivodeship
      • Skórzewo、Greater Poland Voivodeship、波兰、60-185
        • 招聘中
        • AIDPORT Sp. z o.o. ( Site 2118)
        • 接触:
          • Study Coordinator
          • 电话号码:+48570783100
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、波兰、30-727
        • 招聘中
        • Pratia MCM Krakow ( Site 2115)
        • 接触:
          • Study Coordinator
          • 电话号码:+48122958160
    • Masovian Voivodeship
      • Siedlce、Masovian Voivodeship、波兰、08-110
        • 招聘中
        • Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
        • 接触:
          • Study Coordinator
          • 电话号码:+48256403300
      • Warsaw、Masovian Voivodeship、波兰、02-172
        • 招聘中
        • MTZ Clinical Research Powered by Pratia ( Site 2107)
        • 接触:
          • Study Coordinator
          • 电话号码:+48225725959
      • Warsaw、Masovian Voivodeship、波兰、02-781
        • 招聘中
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
        • 接触:
          • Study Coordinator
          • 电话号码:+48225462331
    • Silesian Voivodeship
      • Gliwice、Silesian Voivodeship、波兰、44-102
        • 招聘中
        • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
        • 接触:
          • Study Coordinator
          • 电话号码:+48322788237
    • New South Wales
      • Macquarie University、New South Wales、澳大利亚、2109
        • 暂停
        • Macquarie University ( Site 2700)
    • Queensland
      • Woolloongabba、Queensland、澳大利亚、4102
        • 暂停
        • Princess Alexandra Hospital ( Site 2703)
    • Victoria
      • Melbourne、Victoria、澳大利亚、3000
        • 暂停
        • Peter MacCallum Cancer Centre ( Site 2702)
    • Western Australia
      • Murdoch、Western Australia、澳大利亚、6150
        • 暂停
        • Fiona Stanley Hospital ( Site 2704)
    • California
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope Comprehensive Cancer Center ( Site 0129)
        • 接触:
          • Study Coordinator
          • 电话号码:877-817-9982
      • Irvine、California、美国、92618
        • 招聘中
        • City of Hope Lennar Foundation Cancer Center ( Site 0142)
        • 接触:
          • Study Coordinator
          • 电话号码:see site 0129
    • Georgia
      • Marietta、Georgia、美国、30060
        • 招聘中
        • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
        • 接触:
          • Study Coordinator
          • 电话号码:770-281-5124
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • 招聘中
        • University of Louisville, James Graham Brown Cancer Center ( Site 0133)
        • 接触:
          • Study Coordinator
          • 电话号码:502-562-4673
      • Louisville、Kentucky、美国、40207
        • 招聘中
        • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
        • 接触:
          • Study Coordinator
          • 电话号码:502-899-3366
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Beth Israel Deaconess Medical Center ( Site 0139)
        • 接触:
          • Study Coordinator
          • 电话号码:617-667-7000
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Dana Farber Cancer Institute ( Site 0135)
        • 接触:
          • Study Coordinator
          • 电话号码:617-632-3000
    • Michigan
      • Grand Rapids、Michigan、美国、49503
        • 招聘中
        • The Cancer and Hematology Centers ( Site 0123)
        • 接触:
          • Study Coordinator
          • 电话号码:616-954-9800
    • Missouri
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University School of Medicine ( Site 0114)
        • 接触:
          • Study Coordinator
          • 电话号码:314-362-7355
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
        • 接触:
          • Study Coordinator
          • 电话号码:551-996-5900
      • Morristown、New Jersey、美国、07960
        • 招聘中
        • Atlantic Health System Morristown Medical Center ( Site 0109)
        • 接触:
          • Study Coordinator
          • 电话号码:973-971-7960
    • New York
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center ( Site 0126)
        • 接触:
          • Study Coordinator
          • 电话号码:347-798-9213
    • Tennessee
      • Germantown、Tennessee、美国、38138
        • 招聘中
        • The West Clinic, P.C. ( Site 0115)
        • 接触:
          • Study Coordinator
          • 电话号码:901-683-0055
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • UT Southwestern Medical Center ( Site 0119)
        • 接触:
          • Study Coordinator
          • 电话号码:214-648-3111
      • Birmingham、英国、B15 2GW
        • 招聘中
        • University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
        • 接触:
          • Study Coordinator
          • 电话号码:+4407789651543
      • Cardiff、英国、CF14 2TL
        • 招聘中
        • Velindre Cancer Centre ( Site 2612)
        • 接触:
          • Study Coordinator
          • 电话号码:+442920615888
      • Southampton、英国、SO16 6YD
        • 招聘中
        • University Hospital of Southampton ( Site 2606)
        • 接触:
          • Study Coordinator
          • 电话号码:023 8077 7222
    • Cambridgeshire
      • Cambridge、Cambridgeshire、英国、CB2 0QQ
        • 招聘中
        • Addenbrookes Hospital ( Site 2605)
        • 接触:
          • Study Coordinator
          • 电话号码:+441223805000
    • Edinburgh, City of
      • Edinburgh、Edinburgh, City of、英国、EH4 2XU
        • 招聘中
        • Western General Hospital ( Site 2608)
        • 接触:
          • Study Coordinator
          • 电话号码:+441315371398
    • Glasgow City
      • Glasgow、Glasgow City、英国、G12 0YN
        • 招聘中
        • The Beatson West of Scotland Cancer Centre ( Site 2602)
        • 接触:
          • Study Coordinator
          • 电话号码:+441413019916
    • Leicestershire
      • Leicester、Leicestershire、英国、LE1 5WW
        • 招聘中
        • Leicester Royal Infirmary ( Site 2604)
        • 接触:
          • Study Coordinator
          • 电话号码:0300 303 1573
    • London, City of
      • Northwood、London, City of、英国、HA6 2RN
        • 招聘中
        • Mount Vernon Hospital ( Site 2607)
        • 接触:
          • Study Coordinator
          • 电话号码:+4401923826111
    • Manchester
      • Withington、Manchester、英国、M20 4BX
        • 招聘中
        • The Christie Hospital NHS Foundation Trust ( Site 2601)
        • 接触:
          • Study Coordinator
          • 电话号码:0161 918 2546
    • Limburg
      • Maastricht、Limburg、荷兰、6229 HX
        • 招聘中
        • Maastricht UMC+ ( Site 1901)
        • 接触:
          • Study Coordinator
          • 电话号码:+31433877025
    • North Holland
      • Amsterdam、North Holland、荷兰、1066 CX
        • 招聘中
        • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
        • 接触:
          • Study Coordinator
          • 电话号码:+3120 512 9111
    • South Holland
      • Schiedam、South Holland、荷兰、3118 JH
        • 招聘中
        • Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
        • 接触:
          • Study Coordinator
          • 电话号码:+31108931441
      • The Hague、South Holland、荷兰、2545 AA
        • 招聘中
        • Haga Ziekenhuis locatie Leyweg ( Site 1906)
        • 接触:
          • Study Coordinator
          • 电话号码:+3170 210 2143
      • Barcelona、西班牙、08035
        • 招聘中
        • Hospital Universitari Vall d Hebron ( Site 2303)
        • 接触:
          • Study Coordinator
          • 电话号码:+34934894350
      • Las Palmas、西班牙、35016
        • 招聘中
        • Hospital Insular de Gran Canaria ( Site 2308)
        • 接触:
          • Study Coordinator
          • 电话号码:+34928441738
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre ( Site 2300)
        • 接触:
          • Study Coordinator
          • 电话号码:+34913908339
      • Valencia、西班牙、46009
        • 招聘中
        • Fundación Instituto Valenciano de Oncología ( Site 2307)
        • 接触:
          • Study Coordinator
          • 电话号码:+34961114229
    • Andalusia
      • Seville、Andalusia、西班牙、41013
        • 招聘中
        • Hospital Universitario Virgen del Rocio ( Site 2306)
        • 接触:
          • Study Coordinator
          • 电话号码:+34955013068
    • Barcelona
      • L'Hospitalet de Llobregat、Barcelona、西班牙、08908
        • 招聘中
        • Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
        • 接触:
          • Study Coordinator
          • 电话号码:+34932607744
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、西班牙、28007
        • 招聘中
        • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
        • 接触:
          • Study Coordinator
          • 电话号码:+34914269393
      • CABA、阿根廷、C1426ANZ
        • 招聘中
        • Instituto Alexander Fleming ( Site 0252)
        • 接触:
          • Study Coordinator
          • 电话号码:+541132218900
      • La Rioja、阿根廷、X5004BAL
        • 招聘中
        • Centro Oncológico Riojano Integral ( Site 0256)
        • 接触:
          • Study Coordinator
          • 电话号码:+543804436443X108
      • San Juan、阿根廷、J5402BGA
        • 招聘中
        • COE (Centro Oncológico de Excelencia) ( Site 0259)
        • 接触:
          • Study Coordinator
          • 电话号码:+54 2644229585
    • Buenos Aires
      • CABA、Buenos Aires、阿根廷、C1426AHB
        • 招聘中
        • Centro Oncologico Korben ( Site 0254)
        • 接触:
          • Study Coordinator
          • 电话号码:+541159507952
      • Ciudad de Buenos Aires、Buenos Aires、阿根廷、1181
        • 招聘中
        • Hospital Italiano de Buenos Aires ( Site 0253)
        • 接触:
          • Study Coordinator
          • 电话号码:+541149590200
      • Mar del Plata、Buenos Aires、阿根廷、B7600FZO
        • 招聘中
        • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
        • 接触:
          • Study Coordinator
          • 电话号码:+542234963224
    • Córdoba Province
      • Río Cuarto、Córdoba Province、阿根廷、X5800ALB
        • 招聘中
        • Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
        • 接触:
          • Study Coordinator
          • 电话号码:+543584620273
    • Santa Fe Province
      • Rosario、Santa Fe Province、阿根廷、S2000DSV
        • 招聘中
        • Sanatorio Parque ( Site 0251)
        • 接触:
          • Study Coordinator
          • 电话号码:+5493416955611
      • Rosario、Santa Fe Province、阿根廷、S2000KZE
        • 招聘中
        • Instituto de Oncología de Rosario ( Site 0257)
        • 接触:
          • Study Coordinator
          • 电话号码:+543414484830
      • Seoul、韩国、05505
        • 招聘中
        • Asan Medical Center ( Site 2901)
        • 接触:
          • Study Coordinator
          • 电话号码:+82-2-3010-5977
      • Seoul、韩国、06351
        • 招聘中
        • Samsung Medical Center ( Site 2902)
        • 接触:
          • Study Coordinator
          • 电话号码:+82-2-3410-1767
      • Seoul、韩国、03722
        • 招聘中
        • Severance Hospital, Yonsei University Health System ( Site 2903)
        • 接触:
          • Study Coordinator
          • 电话号码:+82-2-2228-8138

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
  • Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
  • Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy

Exclusion Criteria:

For exclusion criteria: The main exclusion criteria include but are not limited to the following:

  • Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
  • Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
  • Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
  • Has had major surgery within 8 weeks before randomization
  • Has current pneumonitis/interstitial lung disease
  • Has a history of human immunodeficiency virus infection
  • Has Hepatitis B or Hepatitis C virus infection
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has a history of solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Belzutifan + Zanzalintinib

Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months.

Tablet for oral administration.

其他名称:
  • MK-6482
  • PT2977
  • 威利格

Tablet for oral administration.

其他名称:
  • XL092
有源比较器:Belzutifan + Placebo

Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months.

Tablet for oral administration.

其他名称:
  • MK-6482
  • PT2977
  • 威利格

Zanzalintinib-matching placebo tablet for oral administration.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free Survival (PFS)
大体时间:Up to approximately 30 months

PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first.

Up to approximately 30 months
Overall Survival (OS)
大体时间:Up to approximately 50 months

OS is defined as the time from randomization to death due to any cause.

Up to approximately 50 months

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:Up to approximately 30 months

ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.

Up to approximately 30 months
Duration of Response (DOR)
大体时间:Up to approximately 30 months

DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.

Up to approximately 30 months
Number of Participants Who Experience One or More Adverse Events (AEs)
大体时间:Up to approximately 25 months

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported.

Up to approximately 25 months
Number of Participants who Discontinue Study Treatment Due to an AE
大体时间:Up to approximately 24 months

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 24 months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
大体时间:Baseline and up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented.

Baseline and up to approximately 25 months
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
大体时间:Baseline and up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented.

Baseline and up to approximately 25 months
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
大体时间:Baseline and up to approximately 25 months

The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported.

Baseline and up to approximately 25 months
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
大体时间:Baseline and up to approximately 25 months

The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome.

Baseline and up to approximately 25 months
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
大体时间:Up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.

Up to approximately 25 months
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
大体时间:Up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.

Up to approximately 25 months
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
大体时间:Up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome.

Up to approximately 25 months
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
大体时间:Up to approximately 25 months

TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome.

Up to approximately 25 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 研究主任:Medical Director、Merck Sharp & Dohme LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月9日

初级完成 (估计的)

2030年11月27日

研究完成 (估计的)

2030年11月27日

研究注册日期

首次提交

2026年3月20日

首先提交符合 QC 标准的

2026年3月20日

首次发布 (实际的)

2026年3月24日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 6482-034
  • U1111-1311-4692 (注册表标识符:UTN)
  • 2024-516993-31-00 (注册表标识符:EU CT)
  • LITESPARK-034 (其他标识符:MSD)
  • MK-6482-034 (其他标识符:MSD)
  • LS-034 (其他标识符:MSD)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅